Artemis Medicare Services Limi (ARTEMISMED) Fundamentals 2026 — P/E 39.0x, Revenue Analysis | SniperIQ
Artemis Medicare Services Limi (ARTEMISMED) is a India-listed Healthcare company in Medical - Care Facilities with a market capitalization of ₹4,323 Crore, trading at ₹273.65 on the BSE. This SniperIQ fundamentals page covers Artemis Medicare Services Limi's valuation (P/E 39.0x, P/B 4.6x), profitability (net margin 9.6%), revenue (₹1,081 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Artemis Medicare Services Limi's market cap?
Artemis Medicare Services Limi (ARTEMISMED) has a market capitalization of approximately ₹4,323 Crore, trading at ₹273.65 on the BSE. Market cap moves with the live share price.
What is Artemis Medicare Services Limi's P/E ratio?
Artemis Medicare Services Limi's trailing twelve-month P/E ratio is 39.0x, with a price-to-book (P/B) of 4.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Artemis Medicare Services Limi?
Artemis Medicare Services Limi runs a net profit margin of 9.6%, a gross margin of 19.9%, and an operating margin of 13.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Artemis Medicare Services Limi generate?
Artemis Medicare Services Limi reported revenue of ₹1,081 Crore for fiscal year 2026, with net income of ₹104 Crore and earnings per share (EPS) of 6.56. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Artemis Medicare Services Limi pay a dividend?
Artemis Medicare Services Limi offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Artemis Medicare Services Limi financially healthy?
Artemis Medicare Services Limi carries a debt-to-equity ratio of 0.28x and a current ratio of 1.74x, with a market beta of 2.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Artemis Medicare Services Limi a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Artemis Medicare Services Limi (ARTEMISMED) the key facts are: market cap ₹4,323 Crore, P/E 39.0x, revenue ₹1,081 Crore, 52-week range 271.3-279.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Artemis Medicare Services Limi's full fundamentals live
Get Artemis Medicare Services Limi's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.